These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6372 related articles for article (PubMed ID: 2492121)

  • 1. The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice.
    Marincola FM; Drucker BJ; Keeling CA; Siao DY; Starnes HF; Goodwin DA; Holder WD
    Surgery; 1989 Jan; 105(1):79-85. PubMed ID: 2492121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.
    Drucker BJ; Marincola FM; Siao DY; Donlon TA; Bangs CD; Holder WD
    In Vitro Cell Dev Biol; 1988 Dec; 24(12):1179-87. PubMed ID: 3264833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
    Blanchard DK; Serbousek D; Djeu JY
    Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
    Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
    Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of LAK cells and BRM on the growth of pancreatic cancer cells injected into nude mice].
    Asano H; Kobari M; Yusa T; Kawakami K; Matsuno S
    Nihon Geka Gakkai Zasshi; 1994 Sep; 95(9):678-88. PubMed ID: 7838109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-tumor effect of LAK (lymphokine activated killer) cells against human bladder tumors transplanted to nude mouse].
    Tsujihashi H; Ishihara H; Nakanishi A; Matsuda H; Uejima S; Akiyama T; Kurita T
    Nihon Hinyokika Gakkai Zasshi; 1989 Feb; 80(2):204-9. PubMed ID: 2787443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK; Leland P
    Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
    Rodolfo M; Salvi C; Parmiani G
    Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models.
    Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K
    Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 319.